Developer docs
API playgroundTry for free, no card

Search company profiles

Molecule AI

Full company profile

uuid003q1gy

Namestring
Molecule AI
Legal namestring
Molecule AI Private Limited
Websiteurl
moleculeai.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Molecule AI (operating name; previously known as KnowDis) is a Delhi-headquartered, India-incorporated private company that builds MoleculeGEN, a SaaS platform applying AI to early-stage pharmaceutical discovery. The platform targets pharmaceutical companies, biotech firms, contract research organizations, academic researchers and individual computational/medicinal chemists, with use cases spanning de novo target-aware molecule generation, virtual screening, ADMET prediction, lead optimization, and molecular dynamics simulation.

The product stack is built on what the company describes as 'Biophysics Meets Deep Learning' — proprietary architectures grounded in biophysics principles and intended to extend beyond protein structure prediction (e.g., AlphaFold) toward end-to-end small-molecule design. Core modules include De Novo Generation (generative molecular design from atomic building blocks), ADMET Prediction (AI models for absorption, distribution, metabolism, excretion and toxicity), Virtual Screening, Lead Optimisation (generative AI for QSAR generation and property optimization), Molecular Dynamics interfaces, and a MoleculeAI Labs preview module for upcoming capabilities. Research is anchored by a collaboration with IIT Delhi (active since February 2023), which produced co-authored work including the TAGMol paper at ICML 2024, and the company holds five pending WIPO patent applications covering novel sulfonylurea/sulfoximineurea derivatives, NLRP3 inhibitors and neuroinflammatory treatments.

The business model is subscription-based SaaS delivered through app.moleculeai.com, combined with a sales-assisted demo motion (Calendly) targeting enterprise accounts. Distribution is positioned as global, though India is the only named operating geography. Molecule AI was acquired by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) for $8 million in February 2026 (following an October 2025 LOI at $10 million), transitioning it into a subsidiary of a US-listed pharmaceutical group; its website remains active.

Short descriptiontext

Molecule AI (Delhi, India) builds MoleculeGEN, an AI-driven SaaS platform for de novo molecule generation, virtual screening, ADMET prediction and lead optimization, serving pharmaceutical, biotech, CRO and academic drug-discovery users. Acquired by Shuttle Pharmaceuticals (NASDAQ:SHPH) in February 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew Delhi, India
HQ citystring
New Delhi
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, AI drug discovery, computational chemistry software, de novo molecule generation, pharmaceutical AI software
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
Product category
AI-Driven Drug Discovery Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SaaS Platform Subscription
TypeSubscription Recurring
Description

Molecule GEN is offered as a software-as-a-service (SaaS) platform with subscription-based access. Users can book demos and access the platform through app.moleculeai.com, indicating a subscription/recuring revenue model.

moleculeai.com
2Platform Usage
TypeSubscription Recurring
Description

The platform offers built-in, tailor-made workflows for rational and AI-based de novo drug design, suggesting usage-based or tiered subscription pricing.

moleculeai.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1MoleculeGEN
Description

Proprietary AI-powered integrated drug discovery SaaS platform offering de novo molecule generation, virtual screening, ADMET prediction, lead optimization, molecular dynamics, and molecule design tools.

moleculeai.com
Core offering1 text field

Molecule AI develops and sells Molecule GEN, an AI-driven drug discovery SaaS platform offered as a cloud-based subscription product. The platform provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization, ADMET prediction, virtual screening, molecular dynamics simulation, and interactive molecule design tools for pharmaceutical and biotech researchers. It is built on proprietary deep learning architectures grounded in biophysics principles and integrates generative AI, predictive analytics, and computational chemistry into a single end-to-end workflow accessible at app.moleculeai.com.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Featured in Inc42's '5 AI Startups To Watch' December 2025 series recognizing India's AI innovation
+1 more record
Product overview1 text field

Molecule AI offers Molecule GEN as its primary integrated AI-driven drug discovery SaaS platform, designed for end-to-end therapeutic development. The platform combines multiple modules including De Novo Generation (AI-driven target-aware molecule creation), Virtual Screening (computational chemistry-based molecule sifting), ADMET Prediction (AI-based drug-likeness and toxicity assessment), and Lead Optimisation (generative AI for property optimization). Supporting tools include Molecular Dynamics interfaces, Molecule Design editors, and Utilities for molecular analysis. MoleculeAI Labs provides early access to upcoming features. The platform is built around multidisciplinary teams combining AI experts with computational and medicinal chemists, leveraging biophysics principles and deep learning architectures.

Product and service1 record
1Molecule GEN
CategoryAI-Driven Drug Discovery Platform
Description

One-stop, end-to-end AI-driven drug discovery SaaS platform that provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization capabilities. Integrates ADMET prediction, AI-enhanced virtual screening, molecular dynamics simulation, and interactive molecule design tools. Built-in intelligence and heuristics allow researchers of all skill levels to translate research ideas and expedite discovery of new therapeutic candidates for pharmaceutical and biotech companies, contract research organizations, and academic research institutions.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeOthersAnnounced on2025-10-10
Description

Shuttle Pharmaceuticals signed a non-binding Letter of Intent to acquire Molecule.ai (Canadian AI firm) for $10 million subject to milestones. The LOI was later converted to a completed acquisition for $8 million.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-23
Description

KnowDis (parent company of Molecule AI) and IIT-Delhi collaboration for AI-driven antibody design. The partnership focuses on generative AI for drug discovery and has resulted in co-authored publications including TAGMol paper at ICML 2024.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Isomorphic Labs
TypeEmerging player
Description

Alphabet-backed drug discovery company building on DeepMind's protein-structure work for end-to-end small-molecule design; comparable as an emerging AI-first drug discovery venture targeting pharma collaborations, with deeper capital and proprietary protein-modeling lineage.

TypeDirect peer
Description

AI-driven drug discovery company operating the Pharma.AI platform for target identification, de novo generation, and lead optimization; serves the same pharmaceutical and biotech customers with end-to-end generative AI pipelines overlapping Molecule GEN.

TypeDirect peer
Description

Public computational chemistry and molecular simulation platform offering physics-based software (LiveDesign, Maestro) and drug-discovery services; directly competes with Molecule GEN's computational chemistry and lead optimization capabilities for pharma R&D buyers.

TypeDirect peer
Description

AI-native pharma combining automated drug design with experimental validation; overlaps with Molecule AI's de novo design and lead-to-candidate positioning for pharma and biotech partners.

TypeDirect peer
Description

AI plus robotics drug discovery platform offering de novo molecule generation and solid-form prediction; comparable to Molecule GEN's de novo generation and ADMET modules, with similar enterprise SaaS plus services model.

TypeDirect peer
Description

Techbio company using AI/ML and high-throughput biology for drug discovery; comparable as a peer in the AI-discovery space targeting similar big-pharma partnerships and pipeline build-out.

TypeBroad incumbent
Description

Broad enterprise scientific software portfolio spanning discovery, modeling and lab informatics through BIOVIA; competes with Molecule GEN as part of a much wider life sciences suite serving global pharma R&D.

TypeDirect peer
Description

AI small-molecule discovery company using convolutional neural networks for virtual screening and hit identification; directly comparable to Molecule GEN's virtual screening and ADMET prediction modules for pharma discovery programs.

TypeDirect peer
Description

AI drug discovery company combining knowledge graphs with ML for target identification and molecule design; serves pharma partners in the same AI-discovery category with comparable disease-area partnerships.

10CrushBio (Cradle Bio)
TypeEmerging player
Description

AI platform focused on protein engineering and biologics design; adjacent emerging player in generative biology for drug discovery, sharing the AI-for-discovery positioning with Molecule AI's platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecule AI

AI-Driven Drug Discovery Softwaremoleculeai.com

Molecule AI (Delhi, India) builds MoleculeGEN, an AI-driven SaaS platform for de novo molecule generation, virtual screening, ADMET prediction and lead optimization, serving pharmaceutical, biotech, CRO and academic drug-discovery users. Acquired by Shuttle Pharmaceuticals (NASDAQ:SHPH) in February 2026.

What Molecule AI does

Molecule AI (operating name; previously known as KnowDis) is a Delhi-headquartered, India-incorporated private company that builds MoleculeGEN, a SaaS platform applying AI to early-stage pharmaceutical discovery. The platform targets pharmaceutical companies, biotech firms, contract research organizations, academic researchers and individual computational/medicinal chemists, with use cases spanning de novo target-aware molecule generation, virtual screening, ADMET prediction, lead optimization, and molecular dynamics simulation.

The product stack is built on what the company describes as 'Biophysics Meets Deep Learning' — proprietary architectures grounded in biophysics principles and intended to extend beyond protein structure prediction (e.g., AlphaFold) toward end-to-end small-molecule design. Core modules include De Novo Generation (generative molecular design from atomic building blocks), ADMET Prediction (AI models for absorption, distribution, metabolism, excretion and toxicity), Virtual Screening, Lead Optimisation (generative AI for QSAR generation and property optimization), Molecular Dynamics interfaces, and a MoleculeAI Labs preview module for upcoming capabilities. Research is anchored by a collaboration with IIT Delhi (active since February 2023), which produced co-authored work including the TAGMol paper at ICML 2024, and the company holds five pending WIPO patent applications covering novel sulfonylurea/sulfoximineurea derivatives, NLRP3 inhibitors and neuroinflammatory treatments.

The business model is subscription-based SaaS delivered through app.moleculeai.com, combined with a sales-assisted demo motion (Calendly) targeting enterprise accounts. Distribution is positioned as global, though India is the only named operating geography. Molecule AI was acquired by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) for $8 million in February 2026 (following an October 2025 LOI at $10 million), transitioning it into a subsidiary of a US-listed pharmaceutical group; its website remains active.

Molecule AI firmographics

Firmographics
Name
Molecule AI
Legal name
Molecule AI Private Limited
Website
https://moleculeai.com
Company type
Private
Founded year
2023
Operating status
Acquired
Headcount range
1–10 employees
Short description
Molecule AI (Delhi, India) builds MoleculeGEN, an AI-driven SaaS platform for de novo molecule generation, virtual screening, ADMET prediction and lead optimization, serving pharmaceutical, biotech, CRO and academic drug-discovery users. Acquired by Shuttle Pharmaceuticals (NASDAQ:SHPH) in February 2026.
Ownership category
akta.pro rank

Molecule AI industry classification

Industry
Product category
AI-Driven Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Drug discovery platform
  • AI drug discovery
  • Computational chemistry software
  • De novo molecule generation
  • Pharmaceutical AI software

Where Molecule AI is headquartered

Location

Headquarters

HQ city
New Delhi
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Molecule AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. SaaS Platform Subscription: Molecule GEN is offered as a software-as-a-service (SaaS) platform with subscription-based access. Users can book demos and access the platform through app.moleculeai.com, indicating a subscription/recuring revenue model.
  2. Platform Usage: The platform offers built-in, tailor-made workflows for rational and AI-based de novo drug design, suggesting usage-based or tiered subscription pricing.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Molecule AI product offering

Product offering

Core offering

Molecule AI develops and sells Molecule GEN, an AI-driven drug discovery SaaS platform offered as a cloud-based subscription product. The platform provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization, ADMET prediction, virtual screening, molecular dynamics simulation, and interactive molecule design tools for pharmaceutical and biotech researchers. It is built on proprietary deep learning architectures grounded in biophysics principles and integrates generative AI, predictive analytics, and computational chemistry into a single end-to-end workflow accessible at app.moleculeai.com.

Product overview

Molecule AI offers Molecule GEN as its primary integrated AI-driven drug discovery SaaS platform, designed for end-to-end therapeutic development. The platform combines multiple modules including De Novo Generation (AI-driven target-aware molecule creation), Virtual Screening (computational chemistry-based molecule sifting), ADMET Prediction (AI-based drug-likeness and toxicity assessment), and Lead Optimisation (generative AI for property optimization). Supporting tools include Molecular Dynamics interfaces, Molecule Design editors, and Utilities for molecular analysis. MoleculeAI Labs provides early access to upcoming features. The platform is built around multidisciplinary teams combining AI experts with computational and medicinal chemists, leveraging biophysics principles and deep learning architectures.

Differentiator

Problem solved

Functional benefit

Brands

  • MoleculeGEN: Proprietary AI-powered integrated drug discovery SaaS platform offering de novo molecule generation, virtual screening, ADMET prediction, lead optimization, molecular dynamics, and molecule design tools.

Products and services

  • Molecule GEN One-stop, end-to-end AI-driven drug discovery SaaS platform that provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization capabilities. Integrates ADMET prediction, AI-enhanced virtual screening, molecular dynamics simulation, and interactive molecule design tools. Built-in intelligence and heuristics allow researchers of all skill levels to translate research ideas and expedite discovery of new therapeutic candidates for pharmaceutical and biotech companies, contract research organizations, and academic research institutions.

Quantifiable outcome

  • Featured in Inc42's '5 AI Startups To Watch' December 2025 series recognizing India's AI innovation
  • +1 more outcomes

Companies that use Molecule AI

Customer profile

Segments3 records

Ideal customer profiles3 records

Molecule AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Molecule AI partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Shuttle Pharmaceuticals Holdings, Inc.minorOthers · 10 October 2025Shuttle Pharmaceuticals signed a non-binding Letter of Intent to acquire Molecule.ai (Canadian AI firm) for $10 million subject to milestones. The LOI was later converted to a completed acquisition for $8 million.
  • IIT DelhicoreStrategic or Co-development Partner · 23 February 2023KnowDis (parent company of Molecule AI) and IIT-Delhi collaboration for AI-driven antibody design. The partnership focuses on generative AI for drug discovery and has resulted in co-authored publications including TAGMol paper at ICML 2024.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Molecule AI competitors and assessment

Company assessment

Emerging players

  • Isomorphic Labs: Alphabet-backed drug discovery company building on DeepMind's protein-structure work for end-to-end small-molecule design; comparable as an emerging AI-first drug discovery venture targeting pharma collaborations, with deeper capital and proprietary protein-modeling lineage.
  • CrushBio (Cradle Bio): AI platform focused on protein engineering and biologics design; adjacent emerging player in generative biology for drug discovery, sharing the AI-for-discovery positioning with Molecule AI's platform.

Direct peers

  • Insilico Medicine: AI-driven drug discovery company operating the Pharma.AI platform for target identification, de novo generation, and lead optimization; serves the same pharmaceutical and biotech customers with end-to-end generative AI pipelines overlapping Molecule GEN.
  • Schrödinger, Inc. Public computational chemistry and molecular simulation platform offering physics-based software (LiveDesign, Maestro) and drug-discovery services; directly competes with Molecule GEN's computational chemistry and lead optimization capabilities for pharma R&D buyers.
  • Exscientia: AI-native pharma combining automated drug design with experimental validation; overlaps with Molecule AI's de novo design and lead-to-candidate positioning for pharma and biotech partners.
  • XtalPi: AI plus robotics drug discovery platform offering de novo molecule generation and solid-form prediction; comparable to Molecule GEN's de novo generation and ADMET modules, with similar enterprise SaaS plus services model.
  • Recursion Pharmaceuticals: Techbio company using AI/ML and high-throughput biology for drug discovery; comparable as a peer in the AI-discovery space targeting similar big-pharma partnerships and pipeline build-out.
  • Atomwise: AI small-molecule discovery company using convolutional neural networks for virtual screening and hit identification; directly comparable to Molecule GEN's virtual screening and ADMET prediction modules for pharma discovery programs.
  • BenevolentAI: AI drug discovery company combining knowledge graphs with ML for target identification and molecule design; serves pharma partners in the same AI-discovery category with comparable disease-area partnerships.

Broad incumbents

  • Dassault Systèmes (BIOVIA): Broad enterprise scientific software portfolio spanning discovery, modeling and lab informatics through BIOVIA; competes with Molecule GEN as part of a much wider life sciences suite serving global pharma R&D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Molecule AI social profiles

Digital presence

Molecule AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecule AI leadership team

Management profile

Number of profiles

Profiles6 records

Molecule AI funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecule AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecule AI

What does Molecule AI do?

Molecule AI develops and sells Molecule GEN, an AI-driven drug discovery SaaS platform offered as a cloud-based subscription product. The platform provides de novo target-aware molecule generation (hit-generation), hit-to-lead and lead optimization, ADMET prediction, virtual screening, molecular dynamics simulation, and interactive molecule design tools for pharmaceutical and biotech researchers. It is built on proprietary deep learning architectures grounded in biophysics principles and integrates generative AI, predictive analytics, and computational chemistry into a single end-to-end workflow accessible at app.moleculeai.com.

Is Molecule AI a public or private company?

Molecule AI is a private company. It is classified as corporate owned and is currently acquired.

When was Molecule AI founded?

Molecule AI was founded in 2023. It employs 1 to 10 people.

Where is Molecule AI based?

Molecule AI is headquartered in New Delhi, India, in the Asia region.

How does Molecule AI make money?

Two revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are platform Usage.

Who are Molecule AI's main competitors?

Emerging players on record are Isomorphic Labs and CrushBio (Cradle Bio). Direct peers are Insilico Medicine, Schrödinger, Inc., Exscientia, XtalPi, Recursion Pharmaceuticals, Atomwise and BenevolentAI. Dassault Systèmes (BIOVIA) is listed as a broad incumbent.

Does Molecule AI have an API?

No public API is recorded for Molecule AI.

What industry is Molecule AI in?

Molecule AI's product category is AI-Driven Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewShuttle Pharmaceuticals Holdings, Inc. Q2 2026: Revenue $0 Net loss $(3.15M), EPS $(3.10) — 10-Q SummaryShuttle Pharmaceuticals Holdings reported Q2 2026 revenue of $0 and a net loss of $3.15 million, with diluted EPS of $(3.10), improving from a $3.71 million loss and $(32.91) EPS in the prior quarter. The company is pivoting from clinical development to AI and digital infrastructure, having acquired Molecule.ai assets and completed a merger with United Dogecoin.Stock TitanSHPH Stock Price, News & AnalysisShuttle Pharmaceuticals Holdings announced its strategic shift from oncology-focused clinical trials to AI-driven drug discovery after acquiring Molecule.ai in 2025. The company's new focus involves integrating AI technology to accelerate early-stage drug development processes. It is also managing regulatory and market compliance amid ongoing operational adjustments.WhalesbookIndia's AI Awakening: 5 Startups Igniting a $3.5 Billion Tech Revolution!Inc42's "5 AI Startups To Watch" series profiles five Indian AI startups—Dalvoy AI, Molecule AI, PredCo, Riverline AI, and Vishwa AI—operating across education, healthcare, manufacturing, and finance sectors. India's agentic AI segment is projected to exceed $3.5 billion by 2030, reflecting the broader integration of AI into business operations and decision-making. The article positions this growth as indicative of India's technological advancement and economic potential within its SaaS and startup ecosystems.WhalesbookIndia's AI Awakening: 5 Startups Igniting a $3.5 Billion Tech Revolution!Inc42's '5 AI Startups To Watch' series has profiled five Indian AI ventures—Dalvoy AI, Molecule AI, PredCo, Riverline AI, and Vishwa AI—operating across education, healthcare, manufacturing, and finance sectors, showcasing the breadth of AI innovation in the country. India's agentic AI segment is projected to grow to over $3.5 billion by 2030, reflecting a broader shift where AI is transitioning from a competitive differentiator to an essential business tool. The proliferation of these AI-powered startups signals India's technological advancement and economic potential within its burgeoning SaaS and AI markets.Investing.comShuttle Pharmaceuticals CFO resigns, interim CEO steps in as acting CFO By Investing.comShuttle Pharmaceuticals announced the resignation of CFO Timothy Lorber, with Interim CEO Christopher Cooper assuming the CFO role on an interim basis. This leadership change occurs amidst significant financial challenges, including a 93% year-to-date stock decline and negative EBITDA, while the company simultaneously pursues growth through the acquisition of Molecule.ai and recent financing.Stock TitanShuttle Pharma Acquires Molecule.ai in $8M AI DealShuttle Pharmaceuticals acquired Molecule.ai, a Canadian AI health platform, for $8 million in cash and stock, plus a contingent $2 million tied to performance milestones. An initial $3 million was paid at closing, with the remainder to be determined by Molecule. The deal aims to enhance Shuttle's drug discovery pipeline.Investing.comShuttle Pharmaceuticals acquires AI firm Molecule.ai for $8 million By Investing.comShuttle Pharmaceuticals completed its acquisition of AI firm Molecule.ai for $8 million in a cash-and-stock deal, with a contingent $2 million payment. The small-cap company, valued at $2.93 million, also secured a $2.5 million financing deal. Shuttle plans to integrate Molecule.ai's AI platform into its drug development pipeline.Investing.comShuttle Pharmaceuticals stock falls after closing Molecule.ai acquisition By Investing.comShuttle Pharmaceuticals stock fell 6.6% on Friday after the company announced completion of its acquisition of Canadian artificial intelligence company Molecule.ai for $8 million, paid through a combination of cash and stock, with an additional $2 million contingent on performance milestones. The acquisition was executed through Shuttle's wholly owned subsidiary, 1563868 B.C. Ltd., and includes Molecule.ai's AI platform for molecular modeling and predictive analytics. CEO Chris Cooper stated the deal represents a strategic milestone for advancing precision radiotherapy solutions, while Molecule.ai CEO ZT Zhang highlighted plans to implement next-generation agentic AI systems across Shuttle's development pipeline.